Compare Figs Inc (FIGS) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Figs Inc vs Incyte Corporation — how do they compare? Figs Inc trades at $14.38 (market cap $2.37B), while Incyte Corporation trades at $120.5 (market cap $24.54B). The key difference: Incyte Corporation is far larger — about 10.4× Figs Inc's market cap. Which is the better fit depends on your goals.
| FIGS | INCY | |
|---|---|---|
Market Cap | $2.37B | $24.54B |
Sector | Consumer Cyclical | Health |
52-Week High | $17.12 | $129.93 |
52-Week Low | $6.57 | $81.61 |
Enterprise Value | $2.13B | $20.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIGS trades at $14.41, up 0.14% with strong technical momentum as moving averages signal bullish sentiment. The company reported impressive Q2 2026 results with 29% revenue growth and raised full-year guidance, while maintaining robust gross margins of 68.9%. Recent institutional buying and positive analyst coverage support the stock's upward trajectory despite rich valuation multiples.
Outlook remains positive with accelerating revenue growth and margin expansion, though the premium valuation (P/E 43.2) creates high expectations. Key risks include execution challenges in the second half and competitive pressures in healthcare apparel. The consensus price target of $19.50 suggests 35% upside potential from current levels.
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Figs Inc
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
